Other Events ·
On September 17, 2026, Soligenix stockholders approved an amendment to increase authorized common shares from 75…
SNGXSoligenix, Inc.
On September 17, 2026, Soligenix stockholders approved an amendment to increase authorized common shares from 75 million to 125 million and granted the Board discretion to effect a reverse split between 1-for-2 and 1-for-20 within one year. The company also elected five directors and ratified its auditor. Separately, on June 26, 2026, Soligenix filed a prospectus supplement to increase the maximum aggregate offering amount under its At Market Issuance Sales Agreement with Rodman & Renshaw LLC by $2,500,000, bringing the total available capacity to approximately $8.9 million after previously selling about $6.234 million. Soligenix operates in the biotechnology industry, focusing on developing immunotherapies and vaccines.